126 related articles for article (PubMed ID: 37730962)
21. Blocking interleukin-17 in psoriasis: Real-world experience from the PsoPlus cohort.
Schots L; Soenen R; Blanquart B; Thomas D; Lambert J
J Eur Acad Dermatol Venereol; 2023 Apr; 37(4):698-710. PubMed ID: 36562700
[TBL] [Abstract][Full Text] [Related]
22. Clinical Controversies in Psoriatic Disease: The Use of IL-17i/IL-23i Versus TNFi as First-line Advanced Therapy in Psoriatic Arthritis.
Jadon DR; Kavanaugh A; Leung YY
J Rheumatol; 2022 Jun; 49(6 Suppl 1):26-31. PubMed ID: 35169062
[TBL] [Abstract][Full Text] [Related]
23. Skin Mycobiome of Psoriasis Patients is Retained during Treatment with TNF and IL-17 Inhibitors.
Koike Y; Kuwatsuka S; Nishimoto K; Motooka D; Murota H
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32486022
[TBL] [Abstract][Full Text] [Related]
24. Treatment of Psoriasis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations.
Duffin KC; Mazzuoccolo LD; Cura MJ; Esposito M; Fernandez AP; Gisondi P; Giunta A; Hillary T; Piaserico S; Solomon JA; Merola JF
J Rheumatol; 2023 Jan; 50(1):131-143. PubMed ID: 36319014
[TBL] [Abstract][Full Text] [Related]
25. Interleukin-17 Inhibition in Spondyloarthritis Is Associated With Subclinical Gut Microbiome Perturbations and a Distinctive Interleukin-25-Driven Intestinal Inflammation.
Manasson J; Wallach DS; Guggino G; Stapylton M; Badri MH; Solomon G; Reddy SM; Coras R; Aksenov AA; Jones DR; Girija PV; Neimann AL; Heguy A; Segal LN; Dorrestein PC; Bonneau R; Guma M; Ciccia F; Ubeda C; Clemente JC; Scher JU
Arthritis Rheumatol; 2020 Apr; 72(4):645-657. PubMed ID: 31729183
[TBL] [Abstract][Full Text] [Related]
26. The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: a national cohort study.
Ljung L; Askling J; Rantapää-Dahlqvist S; Jacobsson L;
Arthritis Res Ther; 2014 Jun; 16(3):R127. PubMed ID: 24941916
[TBL] [Abstract][Full Text] [Related]
27. Immunological Effects of Anti‒IL-17/12/23 Therapy in Patients with Psoriasis Complicated by Candida Infections.
Bruno M; Davidson L; Koenen HJPM; van den Reek JMPA; van Cranenbroek B; de Jong EMGJ; van de Veerdonk FL; Kullberg BJ; Netea MG
J Invest Dermatol; 2022 Nov; 142(11):2929-2939.e8. PubMed ID: 35662644
[TBL] [Abstract][Full Text] [Related]
28. Do tumor necrosis factor inhibitors increase cancer risk in patients with chronic immune-mediated inflammatory disorders?
Chen Y; Friedman M; Liu G; Deodhar A; Chu CQ
Cytokine; 2018 Jan; 101():78-88. PubMed ID: 27688201
[TBL] [Abstract][Full Text] [Related]
29. Comparison of the drug retention and reasons for discontinuation of tumor necrosis factor inhibitors and interleukin-6 inhibitors in Japanese patients with elderly-onset rheumatoid arthritis-the ANSWER cohort study.
Jinno S; Onishi A; Dubreuil M; Hashimoto M; Yamamoto W; Murata K; Takeuchi T; Kotani T; Maeda Y; Ebina K; Son Y; Amuro H; Hara R; Katayama M; Saegusa J
Arthritis Res Ther; 2021 Apr; 23(1):116. PubMed ID: 33858490
[TBL] [Abstract][Full Text] [Related]
30. Predictors of Treatment Change Among Patients with Rheumatoid Arthritis Treated with TNF Inhibitors as First-Line Biologic Agent in the USA: A Cohort Study from Longitudinal Electronic Health Records.
Jin Y; Landon JE; Krueger W; Liede A; Desai RJ; Kim SC
BioDrugs; 2022 Jul; 36(4):521-535. PubMed ID: 35771381
[TBL] [Abstract][Full Text] [Related]
31. Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort Study.
Torres T; Puig L; Vender R; Yeung J; Carrascosa JM; Piaserico S; Gisondi P; Lynde C; Ferreira P; Bastos PM; Dauden E; Leite L; Valerio J; Del Alcázar-Viladomiu E; Rull EV; Llamas-Velasco M; Pirro F; Messina F; Bruni M; Licata G; Ricceri F; Nidegger A; Hugo J; Mufti A; Daponte AI; Teixeira L; Balato A; Romanelli M; Prignano F; Gkalpakiotis S; Conrad C; Lazaridou E; Rompoti N; Papoutsaki M; Nogueira M; Chiricozzi A
Am J Clin Dermatol; 2022 Nov; 23(6):891-904. PubMed ID: 35976568
[TBL] [Abstract][Full Text] [Related]
32. Dose reduction of biologics in patients with plaque psoriasis: a review.
van Riel CAM; Michielsens CAJ; van Muijen ME; van der Schoot LS; van den Reek JMPA; de Jong EMGJ
Front Pharmacol; 2024; 15():1369805. PubMed ID: 38606178
[TBL] [Abstract][Full Text] [Related]
33. Effects of TNF-α inhibition
Elliott A; Wright G; Pendleton A; Rooney M
Ther Adv Musculoskelet Dis; 2023; 15():1759720X231179524. PubMed ID: 38024204
[TBL] [Abstract][Full Text] [Related]
34. Real-world risk of new-onset inflammatory bowel disease among patients with psoriasis exposed to interleukin 17 inhibitors.
Wright S; Alloo A; Strunk A; Garg A
J Am Acad Dermatol; 2020 Aug; 83(2):382-387. PubMed ID: 32289401
[TBL] [Abstract][Full Text] [Related]
35. Absolute and Relative Risk of New-Onset Psoriasis Associated With Tumor Necrosis Factor-α Inhibitor Treatment in Patients With Immune-Mediated Inflammatory Diseases: A Danish Nationwide Cohort Study.
Thein D; Egeberg A; Skov L; Loft N
JAMA Dermatol; 2022 Sep; 158(9):997-1004. PubMed ID: 35767240
[TBL] [Abstract][Full Text] [Related]
36. Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio Study.
Gossec L; Siebert S; Bergmans P; de Vlam K; Gremese E; Joven-Ibáñez B; Korotaeva TV; Lavie F; Noël W; Nurmohamed MT; Sfikakis PP; Theander E; Smolen JS
Ann Rheum Dis; 2022 Jun; 81(6):823-830. PubMed ID: 35210262
[TBL] [Abstract][Full Text] [Related]
37. Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis.
Bass AR; Abdel-Wahab N; Reid PD; Sparks JA; Calabrese C; Jannat-Khah DP; Ghosh N; Rajesh D; Aude CA; Gedmintas L; MacFarlane L; Arabelovic S; Falohun A; Mushtaq K; Haj FA; Diab A; Shah AA; Bingham CO; Chan KK; Cappelli LC
Ann Rheum Dis; 2023 Jul; 82(7):920-926. PubMed ID: 37019614
[TBL] [Abstract][Full Text] [Related]
38. Malignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy: analysis of the Australian Rheumatology Association Database (ARAD) prospective cohort study.
Buchbinder R; Van Doornum S; Staples M; Lassere M; March L
BMC Musculoskelet Disord; 2015 Oct; 16():309. PubMed ID: 26481039
[TBL] [Abstract][Full Text] [Related]
39. Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers.
Hellgren K; Dreyer L; Arkema EV; Glintborg B; Jacobsson LT; Kristensen LE; Feltelius N; Hetland ML; Askling J;
Ann Rheum Dis; 2017 Jan; 76(1):105-111. PubMed ID: 27147709
[TBL] [Abstract][Full Text] [Related]
40. Drug-survival profiling of second-line biologic therapy in rheumatoid arthritis: Choice of another tumour necrosis factor inhibitor or a biologic of different mode of action?
Shipa MRA; Di Cicco M; Balogh E; Nitu NA; Mainuddin MD; Bhadauria N; Mukerjee D; Roussou E
Mod Rheumatol; 2023 Jul; 33(4):700-707. PubMed ID: 35920402
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
